B

하이텍팜

106190KOSDAQ기초 의약물질 제조업

60.5 / 100

Reference Date: 2026-06-10

Financial Score31.0 / 40
News Sentiment12.5 / 25
Momentum7.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but Revenue is on a declining trend. Declined 13.8% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

Hitek Pharm is a specialized pharmaceutical company established in 1998, focusing on carbapenem-class antibiotic APIs. Its flagship products, imipenem and ertapenem, leverage strong antibacterial properties and high price competitiveness, with exports accounting for 99.99% of sales, primarily to Europe and Asia. In 2023, the company achieved sales of 77.5 billion KRW and operating profit of 15.56 billion KRW, demonstrating sustained growth.

Number of Employees

130people

Average Salary

59.1M KRW

Score Calculation Basis

Detailed Financial Score

PER
13.23Industry Average 27.718.0Point

Half of industry avg (excellent)

PBR
1.16Industry Average 1.745.5Point

Lower than industry avg (good)

ROE
9.17Industry Average -6.033.5Point

Well below industry avg

Debt Ratio
0.39Industry Average 6.628.0Point

Half of industry avg (excellent)

Trend 2023~20256.0 / 10 points
Revenue Growth Rate
0.5 / 3

Avg ▼4.2% (2-year basis)

Operating Profit Growth Rate
2.5 / 3

Avg ▲18.4% (2-year basis)

ROE Trend
3.0 / 4

Avg ROE 9.7% (improving, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position3.0Point

52w lower range (24%)

Current 14,280Won52-week high 25,00052-week low 10,870
1-month return1.0Point

1m -13.77% (falling)

Volume trend3.0Point

Volume flat

Detailed Disclosure

1 totalPositive 0Neutral 1Negative 0
  • Neutral분기보고서 (2026.03)2026-05-15